RHYTHM PHARMACEUTICALS, INC. Debt and Equity Securities, Gain (Loss)
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Debt and Equity Securities, Gain (Loss) of $615.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtAndEquitySecuritiesGainLoss · last filed 2024-11-06
- RHYTHM PHARMACEUTICALS, INC. debt and equity securities, gain (loss) for the quarter ending 2024-09-30 was $615.00K.
- RHYTHM PHARMACEUTICALS, INC. debt and equity securities, gain (loss) for the quarter ending 2023-09-30 was -$175.00K.
- RHYTHM PHARMACEUTICALS, INC. debt and equity securities, gain (loss) for the quarter ending 2023-06-30 was $40.00K.
- RHYTHM PHARMACEUTICALS, INC. debt and equity securities, gain (loss) for the quarter ending 2023-03-31 was $65.00K.
| Period end | Debt and Equity Securities, Gain (Loss) 3 month | Debt and Equity Securities, Gain (Loss) 6 month | Debt and Equity Securities, Gain (Loss) 9 month |
|---|---|---|---|
| 2024-09-30 | $615.00K 10-Q · filed 2024-11-06 | ||
| 2023-09-30 | -$175.00K 10-Q · filed 2024-11-06 | -$135.00K derived: sum of 2 quarters · filed 2024-11-06 | -$70.00K derived: sum of 3 quarters · filed 2024-11-06 |
| 2023-06-30 | $40.00K 10-Q · filed 2024-11-06 | $105.00K derived: sum of 2 quarters · filed 2024-11-06 | |
| 2023-03-31 | $65.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |